Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

NCT07316686 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.

NCT NCT07316686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07316686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Phase
Phase 1
Overall status
Recruiting
Start date
June 16, 2026
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer (adenocarcinoma)